City Therapeutics Files S-1 Registration Statement for U.S. IPO
City Therapeutics, Inc. (SEC file no. 0002143850) filed its Form S-1 with the SEC on October 15, 2026, initiating its U.S. IPO process. As a biotech firm, this filing marks the first formal step toward listing on NASDAQ or NYSE, followed by SEC review and roadshow activities.
51CFO view：Biotech IPOs demand dual CFO competencies: deep knowledge of ASC 730 R&D capitalization under FDA pathways, plus ability to build defensible expense allocation models from preclinical stages—and articulate non-GAAP metrics (e.g., R&D burn rate) compliantly to the SEC.
City Therapeutics, Inc. (SEC file no. 0002143850) filed its Form S-1 with the SEC on October 15, 2026, initiating its U.S. IPO process. As a biotech firm, this filing marks the first formal step toward listing on NASDAQ or NYSE, followed by SEC review and roadshow activities.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →